PPLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.0
| Stock Code | PPLPHARMA | Market Cap | 23,352 Cr. | Current Price | 176 ₹ | High / Low | 221 ₹ |
| Stock P/E | 30.2 | Book Value | 58.2 ₹ | Dividend Yield | 0.08 % | ROCE | 12.1 % |
| ROE | 10.4 % | Face Value | 10.0 ₹ | DMA 50 | 163 ₹ | DMA 200 | 173 ₹ |
| Chg in FII Hold | 0.51 % | Chg in DII Hold | -0.07 % | PAT Qtr | 313 Cr. | PAT Prev Qtr | 151 Cr. |
| RSI | 60.5 | MACD | 5.84 | Volume | 15,61,862 | Avg Vol 1Wk | 24,22,970 |
| Low price | 132 ₹ | High price | 221 ₹ | PEG Ratio | 0.25 | Debt to equity | 0.12 |
| 52w Index | 48.8 % | Qtr Profit Var | 13.0 % | EPS | 5.27 ₹ | Industry PE | 30.5 |
📊 Chart Analysis: PPL Pharma is trading at ₹176, above both its 50 DMA (₹163) and 200 DMA (₹173), indicating short-term bullish momentum. RSI at 60.5 shows healthy strength without being overbought. MACD at 5.84 confirms positive crossover, supporting upward bias. Bollinger Bands suggest price moving towards the upper band, with resistance near ₹185–₹190.
📈 Volume Trends: Current volume (15,61,862) is below the 1-week average (24,22,970), reflecting reduced participation despite price strength, which may limit breakout potential.
🔑 Momentum Signals: Short-term momentum is bullish. Support lies near ₹170–₹173, while resistance is around ₹185–₹190. Optimal entry zone: ₹170–₹176. Exit zone: ₹185–₹190 if momentum sustains.
📉 Trend Status: The stock is trending upward but showing signs of consolidation due to declining volumes. Sustained move above ₹190 could trigger a breakout, while failure to hold above ₹170 may lead to reversal.
Positive
- ✅ Trading above both 50 DMA and 200 DMA confirms bullish bias.
- ✅ Strong quarterly PAT growth (313 Cr vs 151 Cr) highlights earnings momentum.
- ✅ PEG ratio of 0.25 suggests attractive valuation relative to growth.
- ✅ Low debt-to-equity ratio (0.12) ensures financial stability.
Limitation
- ⚠️ ROCE (12.1%) and ROE (10.4%) are modest compared to peers.
- ⚠️ EPS at ₹5.27 remains relatively low given valuation.
- ⚠️ Current volume below average indicates weak buying conviction.
Company Negative News
- ❌ Slight reduction in DII holdings (-0.07%) reflects cautious domestic sentiment.
Company Positive News
- 🌟 Increase in FII holdings (+0.51%) shows foreign investor confidence.
- 🌟 Strong quarterly profit growth supports positive outlook.
Industry
- 🏥 Industry PE at 30.5 is aligned with PPL Pharma’s PE (30.2), suggesting fair valuation.
- 📊 Pharma sector remains resilient with defensive demand, though competition is intense.
Conclusion
PPL Pharma is in an uptrend with bullish momentum supported by technical indicators. Entry near ₹170–₹176 offers favorable risk-reward, while exits around ₹185–₹190 are optimal unless a breakout above ₹190 occurs. Fundamentals show improving profitability, but modest efficiency ratios warrant cautious optimism.